Lumida
/MNKD
⌘K
MannKind Corp

MannKind Corp

MNKD
$3.75USD↓-1.06%-0.04 today

MARKET CAP

1.2B

P/E (TTM)

75.0x

FWD P/E

—

DAY RANGE

$4 – $4

52W RANGE

$2
$7

AI Summary

Stalk
StalkMedium

MNKD remains range-bound under its descending 200-day SMA between support at 3.90–3.95 and resistance at 4.15–4.20. The medium-term bias is Bullish, reflecting a Stage 2 consolidation with a rounded base, but short-term EMAs are flat and momentum is neutral, offering no immediate timing edge. Execution should be deferred, waiting for either a pullback into the converged 9/20/50 EMA zone near support or a decisive breakout above the 200-day SMA. Structurally, the long-term trend remains Bearish until price can reclaim and hold above the 200-day SMA, which poses the primary risk to this view.

  • ↑Revenue +43% YoY in Q2 to $109.4M; H1 +29% to $199.5M
  • ↑Afrezza pediatric launch sees one-third of top 100 prescribers adopting
  • ↓Net loss $19M in Q2 vs $0.7M income YoY highlights weak profitability
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

MannKind Corporation (NASDAQ: MNKD) specializes in developing advanced therapeutic solutions, particularly focusing on diabetes and pulmonary diseases. The company is notable for its innovative inhaled insulin product, Afrezza, which has gained traction following recent pediatric approvals. MannKind is also advancing its pipeline with products like Furosix ReadyFlow for fluid overload, positioning itself well within the healthcare sector amidst a growing demand for effective diabetes management solutions.

Bull says

  • ↑Revenue +43% YoY in Q2 to $109.4M; H1 +29% to $199.5M
  • ↑Afrezza pediatric launch sees one-third of top 100 prescribers adopting
  • ↑Furosix ReadyFlow sales $22.2M in Q2, up 43% QoQ, expanding pipeline
  • ↑Rubric Capital holds 5.8% stake, reflecting institutional confidence
  • ↑Cash balance $161M post $50M PIPE financing supports runway
  • ↑High growth factor, positive momentum, and strategic leverage support valuation

Bear says

  • ↓Net loss $19M in Q2 vs $0.7M income YoY highlights weak profitability
  • ↓SG&A expenses rose 84% to $58.3M, elevating margin pressure
  • ↓Dependence on pipeline approvals, such as Natendib DPI, adds execution risk
  • ↓Competitive insulin market and prescriber hesitancy may curb Afrezza adoption
  • ↓Loss of co-pay assistance threatens pediatric unit growth
  • ↓Negative earnings yield and weak profitability factors signal financial vulnerability

Investment themes with MNKD

Biotech↓ -1.57%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT
Demographics: Elderly Care↓ -0.50%

Services and products for aging population

UCB.BR · JNJ · AZN

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-09-2025bullish

Transcript signals

Bull points

  • Over the past eight quarters, our revenue has surged by over 250%, a testament to the dedication and innovation of our team.
  • This puts us on a run rate of over $250 million in revenue for 2024.
  • We expect that to start momentarily.
Read full transcript analysis ›